FDA delays approval of Moderna vaccine for teens
The Food and Drug Administration (FDA) is delaying its approval of the COVID-19 vaccine manufactured by Moderna in adolescents in order to first study whether the injection actually increases the risk of a rare cardiac inflammatory condition, myocarditis.
The delay in approval is a consequence of the decision by Sweden and three other Nordic countries to limit or suspend the use of the Moderna vaccine for people under 30, precisely because of concerns of heart problems in children.
Researchers have found a link between rare cases of heart disease in children and the Moderna and Pfizer vaccines, both of which use a relatively new technology called mRNA.
The Journal said the FDA is re-examining data on myocarditis risk among younger men and comparing the results of those who received Moderna's vaccine versus those who received a Pfizer injection. At present, the FDA has not yet determined whether one vaccine is more dangerous than the other, so a further round of investigation is necessary.
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
The article the FDA delays the approval of the Moderna vaccine for adolescents comes from ScenariEconomici.it .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/la-fda-ritarda-lapprovazione-del-vaccino-moderna-per-gli-adolescenti/ on Mon, 18 Oct 2021 07:00:14 +0000.